MeiHua Holdings GroupLtd (SHSE:600873) Has A Pretty Healthy Balance Sheet
MeiHua Holdings GroupLtd (SHSE:600873) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. We can see that MeiHua Holdings Group Co.,Ltd (SHSE:600873) does use debt in its business. But is this debt a concern to shareholders?
霍華德·馬克斯說得很好,他說,與其擔心股價波動,不如擔心「永久性損失的可能性是我擔心的風險...我認識的每個實踐投資者都擔心這一點」。因此,顯而易見的是,當你考慮某隻股票有多大風險時,需要考慮債務,因爲過多的債務可能會拖垮一家公司。我們可以看到梅花生物股份有限公司(SHSE:600873)在業務中確實使用了債務。但這個債務會讓股東擔憂嗎?
Why Does Debt Bring Risk?
爲什麼債務會帶來風險?
Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.
對於一家企業來說,債務和其他負債在無法輕鬆履行這些義務時會變得有風險,無論是通過自由現金流還是以有吸引力的價格籌集資金。 資本主義的一個重要方面是「創造性毀滅」的過程,失敗的企業被它們的銀行無情清算。 不過,更常見(但仍然代價高昂)的情況是公司必須以低價發行股票,永久性稀釋股東權益,以加固其資產負債表。 然而,通過取代稀釋,債務可以成爲需要資本以高回報率投資增長的企業的極好工具。 在考慮一家公司的債務水平時的第一步是綜合考慮其現金和債務。
What Is MeiHua Holdings GroupLtd's Net Debt?
梅花生物股份有限公司的淨債務是多少?
As you can see below, MeiHua Holdings GroupLtd had CN¥3.82b of debt at September 2024, down from CN¥4.08b a year prior. However, it does have CN¥5.65b in cash offsetting this, leading to net cash of CN¥1.84b.
正如您下面所看到的,梅花生物股份有限公司在2024年9月份的債務爲38.2億元人民幣,低於一年前的40.8億元人民幣。然而,它持有56.5億元人民幣的現金,抵消了這筆債務,導致淨現金爲18.4億元人民幣。
How Healthy Is MeiHua Holdings GroupLtd's Balance Sheet?
梅花生物的資產負債表有多健康?
Zooming in on the latest balance sheet data, we can see that MeiHua Holdings GroupLtd had liabilities of CN¥7.27b due within 12 months and liabilities of CN¥1.55b due beyond that. Offsetting this, it had CN¥5.65b in cash and CN¥821.0m in receivables that were due within 12 months. So it has liabilities totalling CN¥2.34b more than its cash and near-term receivables, combined.
深入研究最新的資產負債表數據,我們可以看到梅花生物有一年內到期的負債達到了72.7億人民幣,而12個月後到期的負債爲15.5億人民幣。與此相抵,它擁有56.5億人民幣的現金和82100萬人民幣的應收賬款,這些應收賬款在12個月內到期。因此,它的負債總額比其現金和短期應收賬款總額多出23.4億人民幣。
Since publicly traded MeiHua Holdings GroupLtd shares are worth a total of CN¥29.7b, it seems unlikely that this level of liabilities would be a major threat. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. While it does have liabilities worth noting, MeiHua Holdings GroupLtd also has more cash than debt, so we're pretty confident it can manage its debt safely.
由於公開交易的梅花生物股票總價值達到了297億人民幣,這種負債水平似乎不太可能構成重大威脅。然而,我們認爲值得關注其資產負債表強度,因爲這可能隨時間而變化。雖然有需要注意的負債,但梅花生物也比債務擁有更多的現金,因此我們非常有信心它能安全地管理其債務。
But the bad news is that MeiHua Holdings GroupLtd has seen its EBIT plunge 13% in the last twelve months. If that rate of decline in earnings continues, the company could find itself in a tight spot. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine MeiHua Holdings GroupLtd's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
但壞消息是,過去十二個月裏,梅花生物的EBIt下降了13%。如果盈利下降速度繼續,公司可能會陷入困境。在分析債務時,資產負債表顯然是需要關注的重點。但是未來的盈利,勝過一切,將決定梅花生物能否保持健康的資產負債表。因此,如果你關注未來,你可以查看這份顯示分析師盈利預測的免費報告。
Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. MeiHua Holdings GroupLtd may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Over the last three years, MeiHua Holdings GroupLtd recorded free cash flow worth a fulsome 94% of its EBIT, which is stronger than we'd usually expect. That positions it well to pay down debt if desirable to do so.
最後,儘管稅務人員可能喜歡會計利潤,但貸款人只接受冷硬現金。梅花生物的資產負債表上可能有淨現金,但觀察企業如何將其利潤(EBIT)轉換爲自由現金流是非常有趣的,因爲這將影響其對管理債務的需求和能力。在過去三年裏,梅花生物的自由現金流價值達到了其EBIt的豐厚94%,這比我們通常預期的要強。這使其有能力償還債務,如果需要的話。
Summing Up
總之
We could understand if investors are concerned about MeiHua Holdings GroupLtd's liabilities, but we can be reassured by the fact it has has net cash of CN¥1.84b. And it impressed us with free cash flow of CN¥2.7b, being 94% of its EBIT. So we don't have any problem with MeiHua Holdings GroupLtd's use of debt. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. For instance, we've identified 1 warning sign for MeiHua Holdings GroupLtd that you should be aware of.
我們可以理解投資者對梅花生物集團有限公司的負債感到擔憂,但值得安慰的是,其淨現金爲人民幣18.4億。而且,令我們印象深刻的是其自由現金流爲人民幣27億,相當於其EBIt的94%。因此,我們對梅花生物集團有限公司使用債務並無任何問題。在分析負債水平時,資產負債表是明顯的起點。但最終,每家公司都可能存在超出資產負債表之外的風險。例如,我們已經發現了梅花生物集團有限公司的1個警示標誌,您應該注意。
Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.
當然,如果您是那種喜歡購買沒有債務負擔的股票的投資者,那麼不要猶豫,立即發現我們獨家的淨現金增長股票列表。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。